GlobeNewswire: Lixte Biotechnology Holdings, Inc. Contains the last 10 of 67 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T00:15:21ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853169/0/en/NEW-SCIENTIFIC-PUBLICATION-SHOWS-LB-100-LIXTE-S-LEAD-CLINICAL-COMPOUND-CAN-FORCE-CANCER-CELLS-TO-GIVE-UP-THEIR-CANCER-CAUSING-PROPERTIES.html?f=22&fvtc=4&fvtv=45282NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES2024-03-27T12:30:00Z<![CDATA[LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE CLINICAL TRIALS]]>https://www.globenewswire.com/news-release/2024/03/21/2850210/0/en/LIXTE-Provides-Update-on-Progress-with-LB-100-as-a-PP2A-Inhibitor-to-Enhance-Chemotherapy-and-Immunotherapy-Cancer-Treatments.html?f=22&fvtc=4&fvtv=45282LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments2024-03-21T12:30:00Z<![CDATA[-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers --PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s progress with its proprietary compound, LB-100.]]>https://www.globenewswire.com/news-release/2024/02/27/2836045/0/en/Professor-Ren%C3%A9-Bernards-to-Present-New-Pre-Clinical-Data-on-LIXTE-s-LB-100-at-Joint-Conference-of-European-and-American-Associations-for-Cancer-Research.html?f=22&fvtc=4&fvtv=45282Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research2024-02-27T13:30:00Z<![CDATA[Conference In Dublin, Ireland on February 27 - 29, 2024Focuses on How to Bring Basic Science Discoveries to the Clinic]]>https://www.globenewswire.com/news-release/2024/02/26/2835127/0/en/LIXTE-Biotechnology-Enters-into-Exclusive-Immune-Oncology-Patent-License-Agreement-with-NINDS-and-NCI.html?f=22&fvtc=4&fvtv=45282LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI2024-02-26T13:30:00Z<![CDATA[Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies]]>https://www.globenewswire.com/news-release/2024/01/29/2818900/0/en/First-Patient-Dosed-with-LIXTE-s-LB-100-and-GSK-s-Immunotherapy-Dostarlimab-gxly-in-Ovarian-Clear-Cell-Carcinoma-Trial.html?f=22&fvtc=4&fvtv=45282First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial2024-01-29T13:30:00Z<![CDATA[PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LIXTE’s LB-100 to GSK’s programmed death receptor-1 (PD-1)-blocking monoclonal antibody, dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC).]]>https://www.globenewswire.com/news-release/2023/11/13/2779074/0/en/LIXTE-Biotechnology-Provides-Update-on-Clinical-Progress-and-Expanding-Collaborations.html?f=22&fvtc=4&fvtv=45282LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations2023-11-13T13:30:00Z<![CDATA[PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.]]>https://www.globenewswire.com/news-release/2023/10/16/2760671/0/en/LIXTE-Netherlands-Cancer-Institute-and-Oncode-Institute-to-Expand-Collaboration.html?f=22&fvtc=4&fvtv=45282LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration2023-10-16T12:30:00Z<![CDATA[Extension Agreement Follows Successful Two-Year Collaboration in Colon Cancer]]>https://www.globenewswire.com/news-release/2023/10/09/2756673/0/en/LIXTE-Biotechnology-Holdings-Announces-the-Passing-of-its-Founder-John-S-Kovach.html?f=22&fvtc=4&fvtv=45282LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach2023-10-09T12:30:00Z<![CDATA[PASADENA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced the passing of its founder and Executive Chairman, John S. Kovach, M.D.]]>https://www.globenewswire.com/news-release/2023/09/26/2749505/0/en/LIXTE-Appoints-Bas-van-der-Baan-as-President-and-Chief-Executive-Officer.html?f=22&fvtc=4&fvtv=45282LIXTE Appoints Bas van der Baan as President and Chief Executive Officer2023-09-26T12:30:00Z<![CDATA[Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman]]>Bas van der Baan, Newly Appointed President, CEO, Vice Chairman, LIXTE Biotechnology HoldingsLixte Biotechnology Holdings, Inc.https://www.globenewswire.com/news-release/2023/09/20/2746468/0/en/LIXTE-Biotechnology-Announces-a-Supported-Collaborative-Trial-to-Study-LIXTE-s-First-in-Class-PP2A-Inhibitor-LB-100-Plus-GSK-s-Immunotherapy-Dostarlimab-in-Clear-Cell-Ovarian-Cance.html?f=22&fvtc=4&fvtv=45282LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer2023-09-20T12:30:00Z<![CDATA[The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A]]>